TCT 2024: Vivasure Medical to Present US Pivotal Data for PerQseal® Elite
Vivasure Medical®, a leader in fully absorbable technology for percutaneous vessel closure, will reveal the findings from its U.S. PATCH Study at the Transcatheter Cardiovascular Therapeutics (TCT) 2024 conference in Washington, D.C., from October 27-30, 2024. The study evaluates the…
GE HealthCare Launches CareIntellect for Oncology: AI Streamlines Patient Journey for Clinicians
GE HealthCare (Nasdaq: GEHC) has introduced CareIntellect for Oncology, a new cloud-based application that consolidates multi-modal patient data from various systems into a single, streamlined view. Utilizing generative AI, the application summarizes clinical notes and reports, enabling care teams to…
GE HealthCare Launches AI Innovation Lab with Five New Projects
GE HealthCare (Nasdaq: GEHC) today announced a new AI Innovation Lab, an initiative designed to accelerate early-concept AI innovations within the company. These projects are one part of GE HealthCare’s broader AI and digital strategy, which is focused on integrating…
CurrentBody Acquires Tria Beauty, Leaders in At-Home Laser Hair Removal
CurrentBody has successfully acquired Tria Beauty. In 2003, the inventors of LightSheer™, a leading in-clinic laser hair removal technology, aimed to revolutionize at-home hair removal by creating a handheld laser that could deliver permanent results. This innovation led to the…
Oscar Health Expands to New Markets in 2025 to Reach More Americans
Oscar Health, Inc. (NYSE: OSCR), a healthcare technology leader, announced today that it will expand its offerings in the ACA marketplace in 2025. This move aims to provide more individuals, families, and businesses with access to affordable health insurance products,…
MedTech Innovator Reveals 2024 Grand Prize and Award Winners at The MedTech Conference
MedTech Innovator (MTI), the leading accelerator for medical technology companies, has announced that Samay is the 2024 Grand Prize Winner, receiving $350,000 in non-dilutive funding. Based in Mountain View, California, and Medellín, Colombia, Samay is notable for being the first…
Augurex Partners with ARUP Laboratories to Launch 14-3-3η Test for Rheumatoid Arthritis
Augurex Life Sciences Corp., a leader in autoimmune biomarker diagnostics, has announced that ARUP Laboratories, a prominent national reference lab in the U.S., has launched the 14-3-3η test as part of its diagnostic offerings. This agreement is set to significantly…
CareDx Highlights HLA Typing Innovations at ASHI Annual Meeting
CareDx, Inc. (Nasdaq: CDNA), known as The Transplant Company™, announced today new data and product enhancements to be presented at the 50th annual meeting of the American Society for Histocompatibility and Immunogenetics (ASHI) in Anaheim, California, from October 21-25, 2024.…
BeiGene Gets CHMP Nod for TEVIMBRA® in Advanced Gastric and Esophageal Cancers
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued positive opinions recommending an extended authorization for TEVIMBRA® (tislelizumab)…
Endospan Completes Enrollment for NEXUS® Aortic Arch Stent Graft TRIOMPHE IDE Study
Endospan, a leader in endovascular solutions for the Aortic Arch, has announced the completion of enrollment for the primary arm of its TRIOMPHE Investigational Device Exemption (IDE) clinical study, which evaluates the safety and efficacy of the NEXUS® Aortic Arch…
Bruker Unveils $100 High-Accuracy Plasma Proteome for Glycoproteomics and Metaproteomics
At the 23rd Human Proteome Organization World Congress, Bruker Corporation (Nasdaq: BRKR) announced significant advancements in deep, unbiased, and high-sensitivity 4D-Proteomics. These developments enable robust, high-fidelity, large-scale studies while minimizing the inherent cross-talk issues associated with affinity high-plex technologies. A.…
NUCLIDIUM Begins Phase 1 Study of 61Cu Radiotracer in PSMA-Positive Prostate Cancer
NUCLIDIUM has announced the successful imaging of its first patient in a Phase 1 clinical trial for its radiotracer candidate, aimed at providing a safe and accurate diagnostic tool for prostate cancer. The radiotracer, 61Cu-NuriPro™ (61Cu-NODAGA-PSMA I&T), targets Prostate Specific…